Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB)
申请人:——
公开号:US20020052344A1
公开(公告)日:2002-05-02
The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme.
1
The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
A method based on hydroamination mediated by inorganic base was developed for the synthesis of cyclicnitrones from alkenyloximes. DFT calculations of the reaction pathway suggested that this hydroamination could proceed through an unprecedented nucleophilic amination of the unactivated alkene by the oxime nitrogen atom. The transition state of this reaction is stabilized by an ionic interaction between
Iron-Catalyzed Synthesis of Tetrahydronaphthalenes via 3,4-Dihydro-2<i>H</i>-pyran Intermediates
作者:Rebecca B. Watson、Corinna S. Schindler
DOI:10.1021/acs.orglett.7b03367
日期:2018.1.5
The development of an iron(III)-catalyzedsynthetic strategy toward functionalized tetrahydronaphthalenes is described. This approach is characterized by its operational simplicity and is distinct from currently available procedures that rely on [4 + 2]-cycloadditions. Our strategy takes advantage of the divergent reactivity observed for simple aryl ketone precursors to gain exclusive access to tetrahydronaphthalene
A transition-metal-free and base promoted C–C bond forming reaction of benzyl C(sp3)–H bond with organoammonium salts via C–N bondcleavage has been reported. Benzyl ammonium salts as well as cinnamyl ammonium salt could couple readily with various benzyl C(sp3)–H species, producing the corresponding products in moderate to excellent yields with good functional group tolerance. Late stage chemical
Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
申请人:Merck Erosst Canada & Co.
公开号:US06583126B2
公开(公告)日:2003-06-24
The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme.
The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.